<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phenytoin poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phenytoin poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Phenytoin poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark K Su, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allon Amitai, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> (eg, Dilantin) is an anticonvulsant medication used to treat many seizure disorders. It is also a Vaughan-Williams class IB antiarrhythmic agent, although it is now infrequently used for that indication.</p><p><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> toxicity is rarely fatal, but can cause neurologic symptoms ranging from nystagmus to ataxia to coma. Intravenous phenytoin administration may rarely be complicated by the Purple Glove Syndrome.</p><p>The basic pharmacology, presentation, and management of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity will be reviewed here. The clinical use of phenytoin to treat epilepsy and general issues concerning management of the poisoned patient are discussed separately. A summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef56499" href="/d/graphic/56499.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a> and  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> toxicity is associated with few serious adverse events or fatalities [<a href="#rid1">1</a>]. According to the 2015 Annual Report of the American Association of Poison Control Centers (AAPCC) National Poison Data System, 1606 single-substance phenytoin exposures resulted in only 33 major outcomes and two deaths [<a href="#rid1">1</a>]. There were four reported fatalities in cases of multiple-substance exposures in which phenytoin or <a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">fosphenytoin</a> was deemed contributory, but in none of these cases was phenytoin determined to be the primary cause of death. This low prevalence of major outcomes and deaths is similar to that seen in previous years [<a href="#rid2">2</a>].</p><p><a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">Fosphenytoin</a>, a prodrug of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> that is administered parenterally, is believed to have fewer adverse effects than phenytoin. However, there were 29 cases of cardiac events related to fosphenytoin infusion reported to the US Food and Drug Administration (FDA) between 1997 and 2002 [<a href="#rid3">3</a>]. Ten of these resulted in death. Arrhythmias included bradycardia, high degree AV block, and sinus arrest. It is unclear how many of these dysrhythmias can be directly attributed to fosphenytoin, since many of these patients had significant preexisting cardiac pathology or were presumed to be in a state of cardiac stress from status epilepticus. (See  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Phenytoin and fosphenytoin'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> binds to and inhibits voltage-dependent sodium channels, which are found on both neuronal and cardiac tissue. The increased membrane threshold for depolarization after sodium channel blockade lowers the susceptibility of neuronal tissue to epileptogenic stimuli. Excessive inhibition, however, may compromise normal cerebral function, leading to the incoordination and altered mental status characteristic of both acute and chronic phenytoin toxicity.</p><p>Inhibition of sodium channels in cardiac tissue reduces the risk of arrhythmia. <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> shortens cardiac action potentials and prolongs the refractory period between them. Cardiac effects such as dysrhythmias and SA and AV nodal blockade have been reported, especially following intravenous administration of phenytoin [<a href="#rid3">3-5</a>]. Oral phenytoin has only rarely been reported to cause cardiac complications [<a href="#rid6">6</a>].</p><p><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> is available in oral (capsules, tablets, extended-release capsules, and oral suspension) and parenteral formulations. In parenteral formulations, phenytoin is diluted in propylene glycol, which may cause toxicity including hypotension and cardiac dysrhythmias [<a href="#rid7">7</a>]. Oral suspensions of phenytoin may contribute to toxicity due to solubility issues when increased concentrations of the drug are found in the liquid component of inadequately shaken preparations [<a href="#rid8">8,9</a>]. </p><p class="headingAnchor" id="H4"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> is 70 percent bioavailable after oral ingestion [<a href="#rid10">10</a>]. The volume of distribution is approximately 0.5 to 0.8 L/kg, with significant protein binding (to albumin) in vivo. Phenytoin may be displaced from plasma proteins by many drugs, which can result in toxicity [<a href="#rid11">11,12</a>]. At higher serum concentrations of phenytoin, protein binding saturates and free phenytoin concentrations (which determine toxicity) increase dramatically with only modest increases in overall phenytoin concentrations. This fact is important to bear in mind when interpreting toxic serum phenytoin concentrations. A list of drugs that alter serum phenytoin concentrations is provided  (<a class="graphic graphic_table graphicRef82330" href="/d/graphic/82330.html" rel="external">table 2</a>). (See <a class="local">'Laboratory evaluation'</a> below.)</p><p><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> metabolism varies depending upon its serum concentration. Hydroxylation by the cytochrome p450 system is the critical step [<a href="#rid13">13</a>]. Metabolism follows first-order kinetics in the therapeutic range and mild overdoses, meaning that a fixed <strong>percentage</strong> of phenytoin is eliminated over a given period. At higher concentrations, the cytochrome p450 enzyme system becomes saturated, leading to zero-order kinetics in which a fixed <strong>amount</strong> of phenytoin is eliminated over a given period. This alteration in metabolism results in a prolonged half-life (24 to 230 hours in overdose) and contributes to persistently elevated serum concentrations [<a href="#rid14">14,15</a>].</p><p>The metabolism of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> is affected by many substances that interact with the cytochrome p450 system. A large number of drug-drug interactions will either raise or lower serum phenytoin concentrations, depending upon whether they induce or inhibit the p450 system  (<a class="graphic graphic_table graphicRef82330" href="/d/graphic/82330.html" rel="external">table 2</a>) [<a href="#rid11">11</a>]. Cytochrome p450 genetic polymorphism appears to predispose some individuals to phenytoin toxicity secondary to slow metabolism [<a href="#rid16">16,17</a>].</p><p><a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">Fosphenytoin</a> is a prodrug that is converted to <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> by serum and tissue alkaline phosphatases. Fosphenytoin is more expensive than phenytoin and is only available for intravenous and intramuscular administration. The fosphenytoin preparation does not contain propylene glycol and was initially thought to provide a safer means for rapid intravenous infusion, although cardiac toxicity and deaths from fosphenytoin have been reported [<a href="#rid3">3,18</a>]. Literature review demonstrates a similar adverse effect profile to phenytoin [<a href="#rid19">19</a>].</p><p><a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">Fosphenytoin</a> binds to serum proteins and, in the presence of renal or hepatic disease, its plasma concentration will be elevated and its rate of conversion to <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> may accelerate [<a href="#rid20">20</a>]. In addition, fosphenytoin will competitively displace phenytoin from plasma protein binding sites, thereby increasing the concentration of free phenytoin [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H6"><span class="h2">History and drug administration</span><span class="headingEndMark"> — </span>Mild <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity (from overdoses or chronic toxicity) is frequently encountered in patients with epilepsy, particularly after a change in medication dosing. Such patients generally complain of worsening coordination. More serious intoxication is usually seen with intentional ingestions or therapeutic error. Drug interactions and alterations in drug metabolism or physiology may contribute [<a href="#rid21">21</a>]. Intravenous loading of phenytoin in a patient presumed to be noncompliant is a common scenario. To avoid the latter error, we recommend obtaining a serum phenytoin concentration prior to IV loading to treat assumed noncompliance. (See <a class="local">'Management'</a> below.)</p><p>Rapid administration of parenteral <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> and, to a possibly lesser extent, <a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">fosphenytoin</a>, is associated with hypotension, bradyarrhythmias, and occasional asystole [<a href="#rid3">3,22</a>]. These manifestations are avoided by slow (less than 50 mg/min) intravenous administration.</p><p>In cases of overdose with oral <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, the clinician should inquire about depression, intentional self-injury, coingestants, and use of illicit drugs. Additional history regarding trauma, past medical history, and current medications may help to identify comorbidities and coingestants. General issues related to the history and physical examination of the poisoned patient are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Typically, acute <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity does not alter vital signs. However, mild to moderate hypothermia has been described in several case reports [<a href="#rid23">23-26</a>]. One report suggested that hypoadrenalism may have played a role [<a href="#rid26">26</a>], but this has not been reported in other cases. Phenytoin-induced hypothermia is likely uncommon and improves as blood phenytoin concentrations return to a normal range.</p><p>The earliest signs of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity are typically horizontal nystagmus and unsteady gait. More severe toxicity results in slurred speech, along with a gradually worsening mental status typified by lethargy, confusion, or coma. Hyperreflexia is occasionally seen.</p><p>It is difficult to demonstrate a clear correlation between serum drug concentrations and clinical findings, and there is large individual variability. A table outlining approximate correlations is provided  (<a class="graphic graphic_table graphicRef61755" href="/d/graphic/61755.html" rel="external">table 3</a>).</p><p>Although oral <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> has only rarely been reported to cause cardiac complications [<a href="#rid6">6</a>], intravenous infusions of phenytoin or <a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">fosphenytoin</a> can cause hypotension and bradyarrhythmias [<a href="#rid3">3,22</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Drug-induced hypersensitivity syndrome</span><span class="headingEndMark"> — </span>Anticonvulsant hypersensitivity syndrome (AHS) is a rare but potentially life-threatening event associated with aromatic antiepileptics, including <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>. AHS represents an idiosyncratic drug reaction that occurs in 1 in 1000 to 1 in 10,000 patients treated with phenytoin and has a fatality rate of 10 percent. Symptoms vary but classically include fever, rash, lymphadenopathy, and possibly other organ involvement. Pharyngitis is common. When severe, the syndrome can include hepatitis, megaloblastic anemia, rhabdomyolysis, and arteritis. AHS is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2089.html" rel="external">"Drug eruptions", section on 'Drug reaction with eosinophilia and systemic symptoms'</a>.)</p><p>Signs of AHS are usually seen within two months of starting <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> therapy. The diagnosis is frequently missed, and must be considered in any patient taking phenytoin with suggestive symptoms. Patients who develop the hypersensitivity syndrome are at risk for recurrence and may exhibit similar reactions to other anticonvulsants.</p><p class="headingAnchor" id="H9"><span class="h2">Skin and soft tissue</span></p><p class="headingAnchor" id="H541800912"><span class="h3">Toxic epidermal necrolysis and Stevens-Johnson syndrome</span><span class="headingEndMark"> — </span>Patients receiving <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> experience an estimated 1 in 1000 to 1 in 10,000 risk of developing toxic epidermal necrolysis or Stevens-Johnson syndrome. Development of these conditions following phenytoin exposure is idiosyncratic. Most cases occur within the first two months of phenytoin use [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2601826213"><span class="h3">Purple glove syndrome</span><span class="headingEndMark"> — </span>Another uncommon skin complication of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> that is typically associated with intravenous administration is the so-called Purple Glove Syndrome (PGS) [<a href="#rid22">22,28-31</a>]. PGS generally develops within the first 24 hours after infusion and resolves within days to weeks [<a href="#rid32">32-34</a>]. It is not known what proportion of PGS cases resolve without intervention or without significant complications, as serious cases of PGS are rare and milder cases may be unreported. Typically, PGS presents with peripheral edema, blistering, pain, and discoloration of the extremity receiving intravenous phenytoin. Pulses and sensation may be diminished. Superficial venous thrombosis has been noted in histopathological samples, although arterial Doppler studies are usually normal [<a href="#rid32">32,35</a>]. Skin necrosis may develop, and treatment may require surgical intervention.</p><p>The pathophysiology of PGS is poorly understood, although many theoretical mechanisms have been proposed, including chemical irritation from added propylene glycol and sodium hydroxide, vasoconstriction, vasculitis, microthrombus formation, and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> leakage into soft tissue with subsequent edema [<a href="#rid35">35,36</a>]. Extravasation is not uniformly present, and extravasation of phenytoin does not necessarily result in PGS. PGS has been reported after an overdose of oral phenytoin [<a href="#rid37">37</a>]. Use of large bore cannulas or central lines for phenytoin administration has been reported to decrease the incidence of PGS [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Toxic levels of other anticonvulsant agents, such as <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, may present with ataxia and altered mental status. Patients who are postictal may present with an abnormal neurological examination and depressed mental status, although isolated nystagmus and ataxia are unusual. Hypoglycemia should always be considered and ruled out in the setting of altered mental status or new-onset neurological abnormality. Ataxia may be encountered with a broad range of neurological disease and drug toxicities including: cerebellar disease (eg, stroke, hemorrhage, mass), Wernicke's Encephalopathy, ethanol or toxic alcohol overdose, and Parkinson disease. (See  <a class="medical medical_review" href="/d/html/4818.html" rel="external">"Wernicke encephalopathy"</a> and  <a class="medical medical_review" href="/d/html/333.html" rel="external">"Ethanol intoxication in adults"</a> and  <a class="medical medical_review" href="/d/html/4903.html" rel="external">"Clinical manifestations of Parkinson disease"</a>.)</p><p>The differential diagnosis of altered mental status and coma is vast and cannot be fully addressed here, but the emergency clinician should consider alternative infectious, metabolic, vascular, neurologic, toxicological, structural, and traumatic etiologies  (<a class="graphic graphic_table graphicRef59893" href="/d/graphic/59893.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/5104.html" rel="external">"Stupor and coma in adults"</a> and  <a class="medical medical_review" href="/d/html/289.html" rel="external">"Evaluation of abnormal behavior in the emergency department"</a> and  <a class="medical medical_review" href="/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a> and  <a class="medical medical_review" href="/d/html/1661.html" rel="external">"Acute toxic-metabolic encephalopathy in adults"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">LABORATORY EVALUATION</span></p><p class="headingAnchor" id="H12"><span class="h2">Phenytoin concentration</span><span class="headingEndMark"> — </span>Most emergency departments in developed nations can perform total serum <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> concentrations, which often correlate with patient examination findings. Discordant exam findings and serum concentrations should prompt consideration of alternative diagnoses. As an example, the presence of coma is generally not consistent with a serum phenytoin concentration below 30 mg/L (30 microg/mL or 120 micromol/L). However, in the setting of an acute overdose, serum concentrations may be rising rapidly enough to account for progression to coma. Serial measurements of the serum phenytoin concentration should be obtained when patients with an acute overdose deteriorate rapidly.</p><p>A serum albumin concentration may help explain discordance between the serum <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> concentration and clinical symptoms and signs. Hypoalbuminemia results in a higher free phenytoin concentration at any given total phenytoin level. Because it is the free phenytoin concentration that determines toxicity but the total phenytoin concentration that is measured and reported, hypoalbuminemic patients with a therapeutic or mildly elevated phenytoin concentration may exhibit significant toxicity that is greater than expected. </p><p>The Sheiner-Tozer formula may be used to correct for hypoalbuminemia in this setting: </p><div class="formulaContainer"><div class="formula"><p>Corrected total <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> concentration = Observed total phenytoin concentration/([0.2 x Albumin]+0.1); phenytoin in microgram/mL, albumin in g/dL</p></div></div><p>Free <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> concentrations are not routinely measured in hospital laboratories, and this equation may be useful if a patient has signs of phenytoin toxicity despite a "therapeutic" or "sub-therapeutic" phenytoin concentration [<a href="#rid38">38</a>]. However, a systematic review of studies of the Sheiner-Tozer equation found it to be imprecise in a number of clinical situations and prone to bias in some others [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H1654022246"><span class="h2">Liver function and other specific testing</span><span class="headingEndMark"> — </span>Further laboratory testing may include liver function tests and serum electrolytes. Hepatic dysfunction will increase the risk of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity and prolong the effects of intoxication by reducing the rate of metabolism.</p><p>A complete blood count (CBC) rarely affects management. Remember that leukocytosis is commonly encountered after seizures, and a normal white blood cell count does not exclude meningitis or encephalitis. Computed tomography of the brain may be needed to screen for suspected intracranial pathology in patients with stupor or coma.</p><p>In patients with anticonvulsant hypersensitivity syndrome, liver function tests will often show elevated aminotransferases and the CBC with differential will frequently show eosinophilia or marked leukocytosis. Creatine phosphokinase may be elevated if myositis is present [<a href="#rid40">40</a>].</p><p>An electrocardiogram (ECG) reveals the arrhythmias, atrioventricular block, or sinus arrest with junctional or ventricular escape that may occur after intravenous (or very rarely oral) exposure [<a href="#rid3">3,6</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Routine testing of poisoned patient</span><span class="headingEndMark"> — </span>Routine laboratory evaluation of the poisoned patient should include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> and salicylate concentrations, to rule out these common coingestions</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in women of childbearing age</p><p></p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H15"><span class="h2">General approach</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> toxicity is frequently encountered in general emergency practice, and most cases are readily managed with supportive care. Fatalities are rare. Protect the patient from falls secondary to ataxia. Treat nausea and vomiting with antiemetics, such as <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>. A summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef56499" href="/d/graphic/56499.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H16"><span class="h2">Airway and breathing</span><span class="headingEndMark"> — </span>For patients who require endotracheal intubation, standard rapid sequence intubation (RSI) protocols can be used. Most medications used in RSI are safe in patients with <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> intoxication, with the exception of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, which shares phenytoin's antidysrhythmic properties (Vaughan Williams Class IB) and should not be used. (See  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Cardiovascular</span><span class="headingEndMark"> — </span>Symptomatic bradydysrhythmias following intravenous <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> administration are rare [<a href="#rid3">3</a>]. Most resolve soon after stopping the infusion, but some may require transcutaneous or transvenous pacing. Hypotension can be treated with IV boluses of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. If dysrhythmias persist, alternative etiologies should be considered and cardiology consultation obtained. <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">Atropine</a>, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, and <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> remain first line medical treatment for symptomatic bradydysrhythmias. (See  <a class="medical medical_review" href="/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Gastrointestinal decontamination and removal</span><span class="headingEndMark"> — </span>Activated charcoal (AC) may be useful in the setting of a recent ingestion (ie, within several hours). Multiple doses may remove some unbound <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> undergoing enterohepatic circulation, even if the phenytoin was administered intravenously [<a href="#rid41">41</a>], or in cases of chronic phenytoin toxicity [<a href="#rid42">42</a>].</p><p>When considering treatment with AC, clinicians must weigh the potential benefits of treatment with the risks of charcoal aspiration, particularly because nausea, vomiting, and central nervous system depression occur frequently with <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> intoxication.</p><p>We suggest that a single dose of activated charcoal be administered to patients with <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> overdose, unless they manifest a depressed mental status. We do not always use multidose activated charcoal (MDAC), but it appears to be effective. MDAC has been used successfully when phenytoin concentrations have remained persistently elevated secondary to impaired metabolism [<a href="#rid43">43</a>]. Charcoal should be withheld in patients who cannot protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving charcoal. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a>.)</p><p>Gastric lavage and whole bowel irrigation are not recommended in patients with <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity.</p><p class="headingAnchor" id="H2567599393"><span class="h2">Extracorporeal removal</span><span class="headingEndMark"> — </span>Extracorporeal removal of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> via hemodialysis or hemofiltration is usually unnecessary, but phenytoin appears to be moderately dialyzable despite its high protein binding. Following systematic review and analysis of clinical data obtained from 31 patients (30 case reports or case series), the Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup proposes the use of either intermittent hemodialysis (preferred) or hemoperfusion (acceptable) in select cases of severe poisoning with prolonged coma or prolonged incapacitating ataxia [<a href="#rid44">44</a>]. We believe this is a reasonable approach, but recommend consultation with a medical toxicologist if possible when hemodialysis is considered. (See <a class="local">'Additional resources'</a> below.)</p><p class="headingAnchor" id="H19"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Seizures from <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity have been reported, but may stem from a patient's preexisting seizure disorder. Seizures should be treated with benzodiazepines and barbiturates as needed.</p><p class="headingAnchor" id="H20"><span class="h2">Antidotal therapy</span><span class="headingEndMark"> — </span>There is no specific treatment or antidote for <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity.</p><p class="headingAnchor" id="H21"><span class="h2">Hypersensitivity and skin reactions</span><span class="headingEndMark"> — </span>Treatment of the anticonvulsant hypersensitivity syndrome is supportive and includes immediate discontinuation of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> and any other potentially inciting medications (eg, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>). Consultation with a rheumatologist or dermatologist is advised. Glucocorticoids are often used and may be helpful, but conclusive evidence of their efficacy is lacking. (See  <a class="medical medical_review" href="/d/html/2089.html" rel="external">"Drug eruptions"</a>.)</p><p>Patients who develop toxic epidermal necrolysis or Stevens-Johnson syndrome, which are potentially life-threatening conditions, receive standard treatment. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p>The optimal management of Purple Glove Syndrome remains unclear. Case reports describe some improvement with the application of topical <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> and brachial plexus nerve block [<a href="#rid32">32</a>], as well as elevation, application of heat, and soft tissue massage of the affected extremity [<a href="#rid33">33</a>]. Vascular or hand surgical consultation should be obtained in cases of suspected digital or skin necrosis. Anticoagulation is occasionally performed although there is no clear evidence that it is effective [<a href="#rid34">34</a>]; we do not recommend routine anticoagulation unless suggested by the vascular or hand surgery consultant. </p><p>Standard care for cases not involving digital or skin necrosis includes close observation, elevation of the affected limb above the level of the heart, and analgesia. There is not yet sufficient data to formulate strong recommendations about how long an observation period is necessary. Since outcomes can be severe, we recommend a minimum of 24 hours of observation in asymptomatic individuals with PGS.</p><p class="headingAnchor" id="H22"><span class="h2">Monitoring and disposition</span><span class="headingEndMark"> — </span>Patients with acute <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> overdose who are symptomatic should be admitted to the hospital. Serial phenytoin concentrations should be obtained roughly every two hours until the serum concentration begins to fall, as it can increase over the first several hours, especially if gastrointestinal decontamination is inadequate. Falling serum concentrations correlate with clinical improvement, generally noted by the resolution of ataxia, slurred speech, and nystagmus. Once medical symptoms resolve, psychiatric consultation is needed for all cases of intentional ingestion.</p><p>The disposition of the patient with chronic <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity depends on both the degree of toxicity and social circumstances. As a general rule, patients may be discharged home if they can ambulate safely and have someone (eg, family member, partner) who will stay with them and assist with the activities of daily living until toxicity has completely resolved. Patients who cannot ambulate safely or do not have someone to provide assistance should be admitted to the hospital.</p><p class="headingAnchor" id="H24"><span class="h1">PEDIATRIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>Clinicians should maintain a lower threshold to admit children with suspected <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity. Children may manifest clinical signs of phenytoin toxicity at serum concentrations lower than adults. Furthermore, the presentation of significant toxicity may be more subtle and examination findings limited.</p><p>As with adults, the basis for decision-making is clinical evaluation rather than laboratory testing. <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> toxicity should be considered in the differential diagnosis for any pediatric patient with nystagmus and ataxia or altered mental status, and a family member known to take anticonvulsants. Infants and toddlers cannot demonstrate gait ataxia and intoxication may be difficult to detect. These patients may present with indistinct signs such as lethargy, poor feeding, or hypotonia [<a href="#rid45">45</a>].</p><p>Serum drug concentrations above 40 mg/L (40 microg/mL or 160 micromol/L), however, are sufficient reason for admission and observation. Older children with less significant symptoms (eg, nystagmus and mild ataxia), responsible caretakers, and prearranged neurology follow-up may be discharged home with clear instructions to return immediately for any worsening of symptoms.</p><p>Because many cases of lethal <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity in children are due to therapeutic error, children receiving parenteral administrations must be carefully monitored [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4023719"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H997847918"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H2488265984"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> toxicity is associated with few serious adverse events or fatalities. Signs of mild to moderate toxicity (serum concentrations below 40 mg/L [40 microg/mL or 160 micromol/L]) are typically confined to nystagmus, ataxia, slurred speech, nausea, and vomiting. At higher levels of toxicity, mental status can deteriorate to coma, and cardiac dysrhythmias and seizures may occur. A summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef56499" href="/d/graphic/56499.html" rel="external">table 1</a>). (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common iatrogenic causes</strong> – Two common iatrogenic causes of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> intoxication include intravenous (IV) loading of phenytoin in a patient presumed to be noncompliant and overly rapid IV administration. To avoid these errors, a serum phenytoin concentration should be obtained prior to IV loading, and the rate of IV phenytoin administration should be kept below 50 mg/min. (See <a class="local">'History and drug administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Toxic levels of other anticonvulsant agents, such as <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, may also present with ataxia and altered mental status. The differential diagnosis for symptoms consistent with <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> intoxication is broad, and includes hypoglycemia, postictal state, cerebellar disease (eg, stroke, hemorrhage, mass), Wernicke's encephalopathy, and ethanol or toxic alcohol overdose. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – A serum <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> concentration should be obtained whenever poisoning with this drug is suspected. Serial levels can be helpful, particularly if the patient acutely decompensates. Serum concentrations generally correlate with clinical findings. Discordant serum concentrations and clinical signs should prompt consideration of alternative diagnoses. Hypoalbuminemia increases free phenytoin concentrations, which increase toxicity. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> intoxication consists of supportive care. The airway, breathing, and circulation of the rare unstable patient are stabilized as necessary. In patients with phenytoin overdose but without a depressed mental status, we suggest administering a single dose of activated charcoal (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Multiple doses of activated charcoal may be helpful, even among patients with chronic or intravenous toxicity. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1">Hemodialysis and hemoperfusion may be beneficial in select patients with severe toxicity. (See <a class="local">'Extracorporeal removal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition</strong> – Patients who are symptomatic from an acute <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> overdose should be admitted to the hospital. Patients with chronic phenytoin toxicity may generally be discharged home if they can ambulate safely and have someone who will stay with them and assist with the activities of daily living until toxicity has completely resolved. (See <a class="local">'Monitoring and disposition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric considerations</strong> – Children may manifest clinical signs of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> toxicity at serum concentrations lower than adults, so a more liberal threshold for admission and monitoring is used. As with adults, the basis for decision-making is clinical evaluation rather than laboratory testing. Infants and toddlers may present with indistinct signs such as lethargy, poor feeding, or hypotonia. (See <a class="local">'Pediatric considerations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mowry JB, Spyker DA, Brooks DE, et al. 2015 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd Annual Report. Clin Toxicol (Phila) 2016; 54:924.</a></li><li><a class="nounderline abstract_t">Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23:589.</a></li><li><a class="nounderline abstract_t">Adams BD, Buckley NH, Kim JY, Tipps LB. Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. J Emerg Med 2006; 30:75.</a></li><li><a class="nounderline abstract_t">Chua HC, Venketasubramanian N, Tan CB, Tjia H. Paradoxical seizures in phenytoin toxicity. Singapore Med J 1999; 40:276.</a></li><li><a class="nounderline abstract_t">Osorio I, Burnstine TH, Remler B, et al. Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients. Epilepsia 1989; 30:230.</a></li><li><a class="nounderline abstract_t">Su CM, Kung CT, Wang YC, Lu CH. Life-threatening cardiotoxicity due to chronic oral phenytoin overdose. Neurol India 2009; 57:200.</a></li><li><a class="nounderline abstract_t">Mixter CG 3rd, Moran JM, Austen WG. Cardiac and peripheral vascular effects of diphenylhydantoin sodium. Am J Cardiol 1966; 17:332.</a></li><li><a class="nounderline abstract_t">Leventhal LJ, Gould J. Toxic reaction to improperly administered phenytoin suspension. Arch Intern Med 1987; 147:2221.</a></li><li><a class="nounderline abstract_t">Sarkar MA, Garnett WR, Karnes HT. The effects of storage and shaking on the settling properties of phenytoin suspension. Neurology 1989; 39:207.</a></li><li><a class="nounderline abstract_t">Gugler R, Manion CV, Azarnoff DL. Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther 1976; 19:135.</a></li><li class="breakAll">Phenytoin. International programme on chemical safety, poisons information monograph 416. http://www.inchem.org/ (Accessed on October 05, 2006).</li><li class="breakAll">Phenytoin Sodium. Hazardous Substance Data Bank 3160, Revision 2005. http://toxnet.nlm.nih.gov (Accessed on October 05, 2006).</li><li><a class="nounderline abstract_t">Giancarlo GM, Venkatakrishnan K, Granda BW, et al. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 2001; 57:31.</a></li><li><a class="nounderline abstract_t">Holcomb R, Lynn R, Harvey B Jr, et al. Intoxication with 5,5-diphenylhydantoin (Dilantin): clinical features, blood levels, urinary metabolites, and metabolic changes in a child. J Pediatr 1972; 80:627.</a></li><li><a class="nounderline abstract_t">Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63:S3.</a></li><li><a class="nounderline abstract_t">McCluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit Care 2009; 10:222.</a></li><li><a class="nounderline abstract_t">Prasertsup W, Chomchai S, Mekavuthikul P, Phuditshinnapatra J. Phenytoin Intoxication in a Patient Receiving a Therapeutic Dose for Postoperative Seizure Prophylaxis: A Case Study. Ther Drug Monit 2023; 45:573.</a></li><li><a class="nounderline abstract_t">Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996; 46:S3.</a></li><li><a class="nounderline abstract_t">Eriksson K, Keränen T, Kälviäinen R. Fosphenytoin. Expert Opin Drug Metab Toxicol 2009; 5:695.</a></li><li><a class="nounderline abstract_t">Aweeka FT, Gottwald MD, Gambertoglio JG, et al. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999; 40:777.</a></li><li><a class="nounderline abstract_t">Craig S. Phenytoin poisoning. Neurocrit Care 2005; 3:161.</a></li><li><a class="nounderline abstract_t">Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA 1983; 249:762.</a></li><li><a class="nounderline abstract_t">Watters M, Wilson H, Everitt P. Phenytoin-induced hypothermia. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Newberger DS, Blyth SA. Hypothermia and phenytoin toxicity. Clin Neuropharmacol 2003; 26:172.</a></li><li><a class="nounderline abstract_t">Alhaj E, Alhaj N. Hypothermia and phenytoin toxicity: a case report. Clin Neuropharmacol 2001; 24:239.</a></li><li><a class="nounderline abstract_t">Soghoian S, Heinis C, Su M. Phenytoin-induced Hypothermia in a Patient with Mental Retardation. Internet J Neuro 2007; 10.</a></li><li><a class="nounderline abstract_t">Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64:1134.</a></li><li><a class="nounderline abstract_t">Comer, JB. Extravasation from intravenous phenytoin. Intrav Ther Clin Nutr 1984; 11:23.</a></li><li><a class="nounderline abstract_t">Kilarski DJ, Buchanan C, Von Behren L. Soft-tissue damage associated with intravenous phenytoin. N Engl J Med 1984; 311:1186.</a></li><li><a class="nounderline abstract_t">Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia 2001; 42:1156.</a></li><li><a class="nounderline abstract_t">O'Brien TJ, Cascino GD, So EL, Hanna DR. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 1998; 51:1034.</a></li><li><a class="nounderline abstract_t">Santoshi JA, Justin AS, Jacob JI, et al. Purple glove syndrome: a case report. Hand surgeons and physicians be aware. J Plast Reconstr Aesthet Surg 2010; 63:e340.</a></li><li><a class="nounderline abstract_t">Chokshi R, Openshaw J, Mehta NN, Mohler E 3rd. Purple glove syndrome following intravenous phenytoin administration. Vasc Med 2007; 12:29.</a></li><li><a class="nounderline abstract_t">Scumpia AJ, Yahsou J, Cajina J, Cao C. Purple glove syndrome after intravenous phenytoin administration presenting in the emergency department. J Emerg Med 2013; 44:e281.</a></li><li><a class="nounderline abstract_t">Bhattacharjee P, Glusac EJ. Early histopathologic changes in purple glove syndrome. J Cutan Pathol 2004; 31:513.</a></li><li><a class="nounderline abstract_t">Chhabra P, Gupta N, Kaushik A. Compartment syndrome as a spectrum of purple glove syndrome following intravenous phenytoin administration in a young male: a case report and review of literature. Neurol India 2013; 61:419.</a></li><li><a class="nounderline abstract_t">Yoshikawa H, Abe T, Oda Y. Purple glove syndrome caused by oral administration of phenytoin. J Child Neurol 2000; 15:762.</a></li><li><a class="nounderline abstract_t">Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother 1995; 29:667.</a></li><li><a class="nounderline abstract_t">Kiang TK, Ensom MH. A Comprehensive Review on the Predictive Performance of the Sheiner-Tozer and Derivative Equations for the Correction of Phenytoin Concentrations. Ann Pharmacother 2016; 50:311.</a></li><li><a class="nounderline abstract_t">Engel JN, Mellul VG, Goodman DB. Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. Am J Med 1986; 81:928.</a></li><li><a class="nounderline abstract_t">Mauro LS, Mauro VF, Brown DL, Somani P. Enhancement of phenytoin elimination by multiple-dose activated charcoal. Ann Emerg Med 1987; 16:1132.</a></li><li><a class="nounderline abstract_t">Skinner CG, Chang AS, Matthews AS, et al. Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels. Clin Toxicol (Phila) 2012; 50:764.</a></li><li><a class="nounderline abstract_t">Chan BS, Sellors K, Chiew AL, Buckley NA. Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism. Clin Toxicol (Phila) 2015; 53:131.</a></li><li><a class="nounderline abstract_t">Anseeuw K, Mowry JB, Burdmann EA, et al. Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup. Am J Kidney Dis 2016; 67:187.</a></li><li class="breakAll">Barrueto, F, Jr, et al. Antiepileptic Agents. In: Pediatric Toxicology: Diagnosis &amp; Management of the Poisoned Child, Erickson, TB, Ahrens, WR, Aks, SE, et al (Eds), McGraw-Hill, New York 2004. p.283.</li></ol></div><div id="topicVersionRevision">Topic 312 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28004588" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2015 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140178" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434340" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fosphenytoin may cause hemodynamically unstable bradydysrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487084" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Paradoxical seizures in phenytoin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924747" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439856" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Life-threatening cardiotoxicity due to chronic oral phenytoin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5908383" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cardiac and peripheral vascular effects of diphenylhydantoin sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3689080" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Toxic reaction to improperly administered phenytoin suspension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915790" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effects of storage and shaking on the settling properties of phenytoin suspension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1261151" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Phenytoin: pharmacokinetics and bioavailability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1261151" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phenytoin: pharmacokinetics and bioavailability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1261151" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Phenytoin: pharmacokinetics and bioavailability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11372587" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5015071" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intoxication with 5,5-diphenylhydantoin (Dilantin): clinical features, blood levels, urinary metabolites, and metabolic changes in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557548" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19030785" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phenytoin toxicity due to genetic polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37705408" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Phenytoin Intoxication in a Patient Receiving a Therapeutic Dose for Postoperative Seizure Prophylaxis: A Case Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649612" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacology and pharmacokinetics of fosphenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473113" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fosphenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368078" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174888" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phenytoin poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823029" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30674493" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phenytoin-induced hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897633" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hypothermia and phenytoin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479397" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hypothermia and phenytoin toxicity: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phenytoin-induced Hypothermia in a Patient with Mental Retardation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824335" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Extravasation from intravenous phenytoin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6482941" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Soft-tissue damage associated with intravenous phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11580764" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A prospective study of the incidence of the purple glove syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781525" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596627" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Purple glove syndrome: a case report. Hand surgeons and physicians be aware.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17451091" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Purple glove syndrome following intravenous phenytoin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22980417" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Purple glove syndrome after intravenous phenytoin administration presenting in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15239684" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early histopathologic changes in purple glove syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005736" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Compartment syndrome as a spectrum of purple glove syndrome following intravenous phenytoin administration in a young male: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11108512" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Purple glove syndrome caused by oral administration of phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8520077" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26825643" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Comprehensive Review on the Predictive Performance of the Sheiner-Tozer and Derivative Equations for the Correction of Phenytoin Concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3776999" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3662159" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Enhancement of phenytoin elimination by multiple-dose activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22897408" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25597548" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26578149" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
